Influence of pretreatment systolic blood pressure on benefit from carvedilol in severe chronic heart failure patients: Reply  by Cohn, Jay N.
REPLY
Dr. Ghali may be expecting too much from post hoc subgroup
analysis of clinical trial data (1). The sample size in the low blood
pressure subgroup (n  132) is too small to offer any power to
detect a difference in hazard ratio from the other subgroups.
Furthermore, far fewer patients in the low blood pressure subgroup
were at target dose of carvedilol and far more were permanently
discontinued because of adverse effects. Indeed, the similar benefit
of carvedilol in this subgroup despite the lower compliance with
the drug regimen supports the suggestion that the drug, if
tolerated, has a striking benefit in this population.
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In his letter, Dr. Ghali notes that one may expect patients with
heart failure and the lowest systolic blood pressure, those at highest
risk, to enjoy a higher relative benefit from the use of carvedilol.
Indeed, in the COPERNICUS study (1), patients with the lowest
systolic blood pressure were at highest risk. We did not, however,
identify a greater relative benefit with carvedilol. Dr. Ghali invites
us to speculate as to why a greater relative benefit was not found.
At least four possibilities exist.
First, because patients with the lowest systolic blood pressure
had the greatest rate of discontinuation of carvedilol, and less
frequently achieved target dose, it is possible that, if one corrected
for adherence and dose, these patients indeed did derive a greater
relative benefit from carvedilol, when they could tolerate a target
dose. Alternatively, as the relative benefit of bisoprolol (2) and
controlled release metoprolol (3) in patients with somewhat less
severe heart failure was found to be comparable to that of carvedilol
in patients with more severe heart failure, it may be that the
relative benefit of beta-blockers is independent of the severity of
heart failure.
A third possibility is that a relatively greater direct benefit of
carvedilol in patients with the lowest systolic blood pressure was
masked by greater indirect risk associated with excessive hypoten-
sion due to the combined vasodilator and beta-blocking effects of
carvedilol. Whatever the explanation, our study was not powered
to find a difference in subgroups, such that a true beneficial
interaction between systolic blood pressure and carvedilol may have
been missed. Against this possibility is the lack of any trend in
favor of a greater relative benefit in patients with lower systolic
blood pressure randomized to carvedilol.
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Should the Lack of Feasibility
of Conducting Controlled Trials
Influence Evidence-Based Guidelines?
The expert panel/writing group presented evidence-based guide-
lines for cardiovascular disease prevention in women (1). The
researchers stated it is appropriate to consider supporting class I
recommendations with level-B evidence when there is lack of
feasibility of conducting future controlled studies in women. This
method of handling incomplete data constitutes a clear departure
from a pure evidence-based system wherein the lack of evidence,
for whatever reason, weakens the truth value of an issue and should
therefore lead to less strong recommendations. Moreover, this new
approach is ironic given that the hormone replacement therapy
observational data was only found to be incorrect by appropriate
controlled trials. Allowing incomplete data to support class I
recommendations may give the appearance that further studies are
not necessary. One can reasonably argue that, although ethical or
practical reasons may exist not to conduct randomized trials, there
is rarely a pure scientific reason not to do so. To the contrary, such
trials are mandated if cause and effect are to be appropriately
assessed. Even if the cited issues regarding cigarette smoking in
women arguably justify separate handling of pertinent recommen-
dations, it is not at all clear whether such a move can be justified
for the other lifestyle recommendations. I have previously argued
(2) that the single hierarchy system currently used to evaluate the
evidentiary merit of cardiovascular guideline recommendations
may be misleading in the real world, particularly with respect to
opinion evidence. The expert panel’s (1) current departure from
traditional scientific evidence further supports such a revision of
the current single hierarchy evidentiary system. If panel members
wish to assign a stronger truth value to certain evidence under
“justifiable” circumstances they should do so outside the evidence-
based single hierarchy system. As such, the statement could be
made for ethical reasons without degrading the concept of scien-
tific evidence.
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